ESR1 and breast carcinoma: Approximately two thirds of postmenopausal breast cancer cases are estrogen-dependent 4–6, and through years of research, selective estrogen receptor modulators such as tamoxifen have become a cornerstone of treatment, reducing breast cancer recurrence and overall mortality in early-stage disease 7.